1 INTRODUCTION Globally, an estimated 257.5 million people live with chronic hepatitis B virus (HBV) infection and 858,000 die each year of its complications, mainly decompensated cirrhosis and hepatocellular carcinoma (HCC).1 Antiviral therapy with oral nucleo(t)side analogues (NA) effectively reduces the risk of these complications but does not eradicate HBV DNA from the hepatocytes.2-4 Consequently, viral rebound occurs once NA therapy is stopped.
Soo Aleman
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Soo
Contact Soo, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack